"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative

Blood. 2020 Feb 27;135(9):700. doi: 10.1182/blood.2019004164.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Dual-Specificity Phosphatases / genetics*
  • Female
  • Gene Rearrangement
  • Humans
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Lymphoma, Large-Cell, Anaplastic / genetics*
  • Mitogen-Activated Protein Kinase Phosphatases / genetics*
  • Prednisone / administration & dosage
  • Transcription Factors / genetics*
  • Tumor Suppressor Proteins / genetics*
  • Vincristine / administration & dosage

Substances

  • TP63 protein, human
  • Transcription Factors
  • Tumor Suppressor Proteins
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Mitogen-Activated Protein Kinase Phosphatases
  • DUSP22 protein, human
  • Dual-Specificity Phosphatases
  • Prednisone